BTAI BioXcel Therapeutics Inc
Company Analysis
Latest News
BioXcel's Earnings Crater Raises a Brutal Question: Can a Sub-Dollar Biotech Survive Its Own Cash Burn?
Shares of BioXcel Therapeutics plunged 9.2% to $0.71 on August 27 after the company reported second-quarter results that missed Wall Street expectations on...
🔴 BioXcel Therapeutics is trading 9.22% down today after second-quarter earnings reported on August 13, 2026
BioXcel Therapeutics reported its second-quarter earnings on August 13, 2026, with an EPS of -$0.49 and revenue of $0.18 million. The stock is currently...
🔴 BioXcel Therapeutics is trading 10.22% down today
BioXcel Therapeutics is trading 10.22% down now at $0.70, with no clearly reported company-specific announcement identified for August 27, 2026; the immediate...
🟢 BioXcel Therapeutics is trading 5% up today after disclosing $1.25 million in additional term loans
BioXcel Therapeutics is trading 5.07% up at $0.78 after disclosing $1.25 million in additional term loans under its August 24, 2026 credit amendment. - The...
🟢 BioXcel Therapeutics is trading 5.7% up in pre-market after disclosing $1.25 million in additional term loans
BioXcel Therapeutics is trading 5.7% up in pre-market at $0.78 after disclosing $1.25 million in additional term loans under its August 24, 2026 credit...
🔴 BioXcel Therapeutics is trading 5.6% down today after $1.25 million financing, $250,000 fee
BioXcel Therapeutics is trading 5.6% down at $0.72 after announcing a fourteenth credit-agreement amendment on August 24, 2026. - The company secured $1.25...
BioXcel Therapeutics Amends Credit Agreement for $1.25M Loan and Modified Covenants
BioXcel Therapeutics, Inc. has entered into a fourteenth amendment to its credit agreement, securing an additional $1.25 million in term loans. The amendment,...
🔴 BioXcel Therapeutics is trading 5.9% down today after extending liquidity-event deadline
BioXcel Therapeutics is trading at $0.76, down -5.86%, after extending its liquidity-event deadline. - On August 24, BioXcel Therapeutics amended its credit...
BioXcel Therapeutics Amends Credit Agreement, Extends Key Transaction Deadline
BioXcel Therapeutics has entered into the Thirteenth Amendment to its Credit Agreement, extending a crucial deadline for the company to secure a strategic...
🟢 BioXcel Therapeutics is trading 6.25% up in pre-market after Q2 earnings beat and positive SERENITY At-Home data
BioXcel Therapeutics is trading at $0.85 (+6.25%) after recent positive Q2 2026 earnings and reinforced confidence from late-stage SERENITY At-Home data. •...
🟢 BioXcel Therapeutics is trading 5.46% up in after-hours trading after positive late-stage at-home agitation-treatment data
BioXcel Therapeutics is trading 5.46% up at $0.85 in after-hours trading after positive late-stage data for its at-home agitation treatment strengthened...
🟢 BioXcel Therapeutics is trading 5.5% up today after positive late-stage data for at-home agitation treatment
BioXcel Therapeutics is trading 5.5% up at $0.84 after positive late-stage data for its at-home agitation treatment strengthened confidence in the company’s...
BioXcel's Promising Drug Data Meets a Looming Debt Deadline — Can Science Outrun Insolvency?
Shares shifted as BioXcel Therapeutics surged 11.3% to $0.89 after positive late-stage clinical trial results for its at-home agitation treatment bolstered...
🟢 BioXcel Therapeutics is trading 11.33% up in pre-market after positive Phase 3 SERENITY At-Home data
BioXcel Therapeutics is trading 11.33% up at $0.89 in pre-market after investors responded to positive Phase 3 SERENITY At-Home data presented on August 19,...
🟢 BioXcel Therapeutics is trading 5.6% up in pre-market after positive Phase 3 SERENITY At-Home data
BioXcel Therapeutics is trading 5.6% up now at $0.87 after investors responded to positive Phase 3 SERENITY At-Home data presented on August 19, 2026. -...
BioXcel Therapeutics fair value jumps 31%, following Phase 3 trial success
Analysts raised the fair value estimate for BioXcel Therapeutics to approximately $18.33 per share. This represents a 31% increase over the previous valuation....
🟢 BioXcel Therapeutics rises 5.4% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 BioXcel Therapeutics is trading 5.4% up in pre-market after financing deadline extended to August 21, 2026
BioXcel Therapeutics is trading 5.42% up now at $0.83 after an amended credit agreement extended the deadline for securing lender-approved financing or...
🟢 BioXcel Therapeutics trades up 6.39% after credit agreement amendment offers temporary liquidity relief
BioXcel Therapeutics is trading 6.39% up at $0.84 in after-hours, likely reacting to a recent amendment to its credit agreement that eased liquidity covenants...
🔴 BioXcel Therapeutics is trading 10.39% down today after second-quarter results missed EPS and revenue estimates
BioXcel Therapeutics is trading 10.39% down at $0.80 after its August 17, 2026, second-quarter results missed expectations. - EPS was -$0.490 versus -$0.423...